Navigation Links
Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
Date:12/4/2012

c type or that due to lupus erythematosus."  Questcor has also launched a pilot effort in rheumatology, as Acthar is approved for several rheumatology-related conditions including Dermatomyositis, Polymyositis, Lupus and Rheumatoid Arthritis. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.    For more information about Questcor, please visit www.questcor.com.

Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "believes," "continue," "could," "estimates," "expects," "growth," "may," "plans," "potential," "should," "substantial" or "will" or the negative of such terms and other comparable terminology. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following:

  • Our reliance on Acthar for substantially all of our net sales and profits;
  • Research and development risks and our reliance on third-parties to conduct research and development and the ability of research and development to generate successful results;
  • Our ability to receive high reimbursement levels from third party payers;
  • Our ability to comply with federal and state regulations, including regulations relating to pharmaceutical sales and marketing practices;
  • The results of any pending or future litigation, investigations or claims, inclu
    '/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
2. Questcor to Report Second Quarter Results on July 24, 2012
3. Questcor Reports Second Quarter Financial Results
4. Questcor Pharmaceuticals to Present at Investor Conferences in September
5. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
6. Questcor Comments on Insurance Policy Bulletin
7. Questcor to Conduct Conference Call to Discuss Reimbursement Process
8. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
9. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
10. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
11. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... May 1, 2015  Legendary actor and director ... new PBAFacts campaign designed to educate and encourage patients ... about Pseudobulbar Affect (PBA) and to speak with their ... actor has the ability to cry and laugh on ... control experienced by people living with PBA episodes. ...
(Date:5/1/2015)... Semler Scientific, Inc. (Nasdaq: SMLR ), ... and markets products that assist healthcare providers in monitoring ... for the first quarter ended March 31, 2015. ... reported continued progress with year over year growth of ... 14%," said Doug Murphy-Chutorian , M.D., chief executive ...
(Date:5/1/2015)... -- Cambrex Corporation (NYSE: CBM ) reports results for ... Highlights , Sales increased 18% compared to the ... impact, driven by Innovator products and Controlled Substances. , ... first quarter of 2014. , GAAP Diluted EPS from ... last year and Adjusted Diluted EPS was $0.29 compared to ...
Breaking Medicine Technology:Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 2Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 3Semler Reports First Quarter 2015 Financial Results 2Semler Reports First Quarter 2015 Financial Results 3Semler Reports First Quarter 2015 Financial Results 4Semler Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11
... 8 Nektar,Therapeutics (Nasdaq: NKTR ) today ... program to evaluate NKTR-102 (PEG-irinotecan) as a,potential treatment ... using the company,s innovative small molecule,PEGylation technology platform., ... for NKTR-102 in colorectal cancer is,a major achievement ...
... Trial Data and Emerging Clinical Practice Experience Support ... HYLENEX Efficacy ... Therapeutics, Inc.,(Nasdaq: HALO ), a biopharmaceutical company developing and ... publication of the INFUSE-LR clinical trial results in the Journal,of ...
Cached Medicine Technology:Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer 2Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer 3Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer 4Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 2Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 3Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 4Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 5
(Date:5/2/2015)... TX (PRWEB) May 02, 2015 ... skin laxity issues of the face, neck and ... new concept with real potential for the success ... by the ThermiHealth Clinical Advisory Council, ThermiGyn’s Women’s ... FACOG, FACS, ACGE, concluded that ThermiGyn’s temperature controlled ...
(Date:5/2/2015)... the success that Veatch Dental Consulting has had over the ... Alex Shields to the team. With Neida and Alex on ... experience working with dentists to ensure their success. , Neida ... She was certified as dental assistant from Texas State ... showing the importance of oral hygiene to patients, Neida was ...
(Date:5/1/2015)... Islands, BWI (PRWEB) May 02, 2015 ... It is http://www.thevenetiangracebay.com , and it is ... incorporates the stunning white and attractive turquoise hues of ... of Google, sixty seven percent of leisure travelers used ... showed that smartphones were used in the planning and ...
(Date:5/1/2015)... May 01, 2015 Jusuru International has ... the successful repositioning of its flagship nutritional supplement, Liquid ... with a new name, new logo, new packaging, new ... Awards are designed to identify and promote programs that ... , “DSA congratulates Jusuru International for their outstanding ...
(Date:5/1/2015)... The Workgroup for Electronic Data ... the use of health IT to create efficiencies in ... to the United States Government Accountability Office (GAO) for ... in Medicare. The report, “ Potential Uses of Electronically ... to the public on Apr. 24, 2015 and examines ...
Breaking Medicine News(10 mins):Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3Health News:Veatch Dental Consulting Services Welcomes New Team Members 2Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3
... out the best place to live by eavesdropping on ... birds a communication and behavioral trait so strong ... in places they otherwise would have avoided. , This ... had previously been understood, researchers say, and that these ...
... Ill., June 18 Custom print and ... a division,of MediMedia USA, has announced a ... clients the industry-leading, innovative online behavior,change programs ... health information and,engagement solutions., HealthMedia,s online ...
... Fla., June 18 eDiets.com,Inc. (Nasdaq: DIET ... diet,fitness and healthy lifestyle solutions to everyone, has ... effective immediately.,Bringing over 8 years of senior business ... CIO and VP of IT at Sheridan Healthcare ...
... (Pink Sheets: CGCP), a leading developer of ... upcoming scientific,presentation that describes the use of ... (PRP)., The presentation titled "Intramyocardial Injection ... Revascularization" will,be presented by Kurt E. Wehberg, ...
... in the event of a disease pandemic and will be forced ... of sick and dying. In order to protect themselves and allow ... be fully prepared by getting available vaccines now. , But how ... at a time when no threat is imminent, and they are ...
... The American Medical,Association (AMA) announced today the re-election ... surgeon, to his second consecutive,term as vice speaker ... position, Dr.,Gurman will assist in presiding over the ... "I look forward to continuing to encourage physicians ...
Cached Medicine News:Health News:Birds communicate reproductive success in song 2Health News:Birds communicate reproductive success in song 3Health News:StayWell Custom Communications Announces Strategic Alliance With HealthMedia 2Health News:StayWell Custom Communications Announces Strategic Alliance With HealthMedia 3Health News:eDiets.com(R) Appoints New Chief Information Officer Laura Klein 2Health News:eDiets.com(R) Appoints New Chief Information Officer Laura Klein 3Health News:Cardiogenesis Announces Preliminary Results Combining TMR + Platelet Rich Plasma (PRP) 2Health News:Cardiogenesis Announces Preliminary Results Combining TMR + Platelet Rich Plasma (PRP) 3Health News:Cardiogenesis Announces Preliminary Results Combining TMR + Platelet Rich Plasma (PRP) 4Health News:Effective health messages may yield vaccine compliance among ER workers 2
... The NIDEK YC-1800 is an ... laser delivery and output technologies, improved ... offset and compact design with versatility ... YC-1800 replaces the YC-1600 and adds ...
... epTIPS Filter have an integrated ... without "self-sealing" additives. This filter provides ... by aerosols, and it does not ... incorrect pipetting. Samples can then be ...
Lightweight PVC housing for easy transport, integrated handle. Easy lamp exchange....
... • V-shaped bottom allows easy ... lips facilitate pour-out ,• Nesting ring ... Solution Basin designed for 4, 8, and ... V-shaped bottom permits withdrawal of practically all ...
Medicine Products: